FDA approves $2.59 million gene therapy for SMA
The FDA has approved Itvisma (onasemnogene abeparvovec-brve) to treat children two years and older, teens, and adults living with spinal...
SMA
Novartis gene therapy poised to expand SMA treatment landscape – Healthcare News
Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully achieved the primary endpoint in...
